Literature DB >> 16985705

Saw Palmetto Berry as a Treatment for BPH.

E Fagelman, F C Lowe.   

Abstract

Phytotherapeutic agents are often prescribed in Europe for the treatment of benign prostatic hyperplasia with lower urinary tract symptoms and are commonly used in the United States in over-the-counter preparations. Saw palmetto berry is the most popular of these agents, and in vitro some studies suggest that liposterolic extract of the plant has antiandrogenic effects that inhibit the type 1 and type 2 isoenzymes of 5alpha-reductase; however there are no clinical studies that show any decrease in serum dihydrotestosterone or prostate-specific antigen. Its efficacy in the treatment of lower urinary tract symptoms has not been conclusively proven. Clinical efficacy was suggested by a meta-analysis of Permixon, a formulation of saw palmetto, but the meta-analysis was done on suboptimal studies. One trial supports the equivalency of Permixon to finasteride in treating moderate to severe symptoms of benign prostatic hyperplasia, with less decrease in sexual function. However, without a control/placebo arm, the actual efficacy of the agents cannot be determined. Other than occasional gastrointestinal upset, no other side effects have been reported.

Entities:  

Year:  2001        PMID: 16985705      PMCID: PMC1476047     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  19 in total

1.  Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines.

Authors:  L Ravenna; F Di Silverio; M A Russo; L Salvatori; E Morgante; S Morrone; M R Cardillo; A Russo; L Frati; A Gulino; E Petrangeli
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

2.  Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.

Authors:  J C Carraro; J P Raynaud; G Koch; G D Chisholm; F Di Silverio; P Teillac; F C Da Silva; J Cauquil; D K Chopin; F C Hamdy; M Hanus; D Hauri; A Kalinteris; J Marencak; A Perier; P Perrin
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

3.  The Lipidosterolic Extract fromSerenoa repens Interferes with Prolactin Receptor Signal Transduction.

Authors:  P. Vacher; N. Prevarskaya; R. Skryma; M.C. Audy; A.M. Vacher; M.F. Odessa; B. Dufy
Journal:  J Biomed Sci       Date:  1995-10       Impact factor: 8.410

4.  Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers.

Authors:  G Strauch; P Perles; G Vergult; M Gabriel; B Gibelin; S Cummings; W Malbecq; M P Malice
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

Review 5.  Saw palmetto for the treatment of men with lower urinary tract symptoms.

Authors:  G S Gerber
Journal:  J Urol       Date:  2000-05       Impact factor: 7.450

6.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.

Authors:  T J Wilt; A Ishani; G Stark; R MacDonald; J Lau; C Mulrow
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

7.  Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients.

Authors:  F Di Silverio; G D'Eramo; C Lubrano; G P Flammia; A Sciarra; E Palma; M Caponera; F Sciarra
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

8.  Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors.

Authors:  C Iehlé; S Délos; O Guirou; R Tate; J P Raynaud; P M Martin
Journal:  J Steroid Biochem Mol Biol       Date:  1995-09       Impact factor: 4.292

9.  Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.

Authors:  L Rhodes; R L Primka; C Berman; G Vergult; M Gabriel; M Pierre-Malice; B Gibelin
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia.

Authors:  H Weisser; S Tunn; B Behnke; M Krieg
Journal:  Prostate       Date:  1996-05       Impact factor: 4.104

View more
  4 in total

Review 1.  Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia.

Authors:  Youngjoo Kwon
Journal:  Food Sci Biotechnol       Date:  2019-04-17       Impact factor: 2.391

2.  Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study.

Authors:  Yu-Jui Kuo; Fung-Chang Sung; Po-Fan Hsieh; Hui-Ping Chang; Kun-Ling Wu; Hsi-Chin Wu
Journal:  Cancer Med       Date:  2019-04-09       Impact factor: 4.452

3.  Molecular effects of bioactive fraction of Curcuma mangga (DLBS4847) as a downregulator of 5α-reductase activity pathways in prostatic epithelial cells.

Authors:  Agung Heru Karsono; Olivia Mayasari Tandrasasmita; Raymond R Tjandrawinata
Journal:  Cancer Manag Res       Date:  2014-06-06       Impact factor: 3.989

4.  Extracts of Phyllostachys pubescens Leaves Represses Human Steroid 5-Alpha Reductase Type 2 Promoter Activity in BHP-1 Cells and Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Rat Model.

Authors:  Kwang Hoon Song; Chang-Seob Seo; Won-Kyung Yang; Hyun-O Gu; Ki-Joong Kim; Seung-Hyung Kim
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.